Ligand Pharmaceuticals Incorporated
Organization details
- Legal name
- Ligand Pharmaceuticals Incorporated
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LGND
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000886163
- EIN
- 77-0160744
Board of directors
-
Jason Aryeh · DirectorSince 2023
-
Jason Haas · DirectorSince 2023
-
John L. Lamattina · DirectorSince 2023
-
John W. Kozarich · DirectorSince 2023
-
Martine Zimmermann · DirectorSince 2023
-
Nancy Ryan Gray · DirectorSince 2023
-
Stephen L. Sabba · DirectorSince 2023
-
Todd C. Davis · Director · Chief Executive OfficerSince 2023
Chief executives
Director election results
Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.0%
-
92.7%
-
94.4%
-
95.3%
-
96.5%
-
98.1%
-
98.2%
Board connections
4 of this board's directors also sit on 6 other boards. 6 are in the same sector.
-
Candel Therapeutics Inc. Same sectorvia Martine Zimmermann
-
Immunome Inc. Same sectorvia John L. Lamattina
-
Lifecore Biomedical Inc. Same sectorvia Jason Aryeh
-
Orchestra BioMed Holdings Inc. Same sectorvia Jason Aryeh
-
Palvella Therapeutics Inc. Same sectorvia Todd C. Davis
-
Pelthos Therapeutics Inc. Same sectorvia Todd C. Davis
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $34,760,458
- 143 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4, 2026 | Jason Aryeh Director | Open-market sale | −282 | $319.99 | $90,237 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Option exercise | +5,000 | $52.27 | $261,350 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −283 | $307.39 | $86,992 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −708 | $308.43 | $218,369 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −522 | $309.91 | $161,773 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −490 | $310.61 | $152,201 |
| Nov 2, 2026 | Jason Aryeh Director | Open-market sale | −700 | $320.43 | $224,298 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −520 | $311.72 | $162,093 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −634 | $312.85 | $198,350 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −403 | $313.75 | $126,441 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −80 | $314.58 | $25,166 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −280 | $317.91 | $89,014 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −440 | $318.73 | $140,240 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −320 | $319.97 | $102,390 |
| Nov 2, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −200 | $321.44 | $64,288 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Ligand Pharmaceuticals Incorporated
Who is the CEO of Ligand Pharmaceuticals Incorporated?
Todd C. Davis is Ligand Pharmaceuticals Incorporated's Chief Executive Officer.
How many directors are on Ligand Pharmaceuticals Incorporated's board?
Ligand Pharmaceuticals Incorporated's board has 8 directors: Jason Aryeh, Jason Haas, John L. Lamattina, John W. Kozarich, Martine Zimmermann, Nancy Ryan Gray, Stephen L. Sabba and Todd C. Davis.
Are Ligand Pharmaceuticals Incorporated insiders buying or selling shares?
Over the last 12 months, Ligand Pharmaceuticals Incorporated insiders made no open-market purchases and sold $34.8 million of shares in 143 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="ligand-pharmaceuticals-incorporated"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.